abrdn Life Sciences Investors

Morgan Stanley Raises Regeneron Pharmaceuticals Target Price

FDA Approves Amgen's UPLIZNA for Treatment of Adult Generalized Myasthenia Gravis

Regeneron Vice President Marion McCourt Sells Shares to Pay Taxes

Ultragenyx CFO Reports Sale of Company Shares

BMO Capital and Truist Financial Maintain Buy Rating for Regeneron Pharmaceuticals

Nebula Research Increased Stake in Insmed Inc.

Aliram Pharmaceutical Repurchased $51.9 Million Convertible Notes

Wells Fargo Maintains Amgen's Hold Rating, Price Target $325

Wells Fargo Analyst Maintains Hold Rating on Regeneron Pharmaceuticals

Insmed Director Sells $4.1M in Shares, Rothschild Upgrades to Buy

Regeneron Vice President Jason Pitofsky Sells 989 Shares

Insmed to Present Data on Treprostinil and Brensocatib at European Respiratory Society Congress

EDE and Pharmaceutical Information Association Co-host UAE's First Clinical Research Forum

Amgen Becomes Official Biotech Partner for the 2026 LA World Cup

Vaxcyte Inc. Initiates OPUS Phase 3 Clinical Trial for VAX-31 Pneumococcal Vaccine

Regeneron Announces Positive Trial Results for Lynzyfic in Multiple Myeloma

Regeneron to Hold Virtual Investor Meeting to Discuss Multiple Myeloma Project

Wall Street Zen Downgrades Amgen Stock Rating to Buy

Insmed Inc Director Plans to Sell 20,000 Restricted Shares

William Lewis, CEO of Insmed Inc., Disposed of Company Common Stock

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

REGN

Morgan Stanley raised its price target for Regeneron Pharmaceuticals from $767.00 to $768.00, maintaining an "equal weight" rating. Other analysts have varied ratings, with some issuing "buy" and others "hold". The stock is currently trading at $737.58, with a market cap of $77.52 billion. Recent insider transactions and hedge fund activities are noted, with corporate insiders owning 7.02% of the stock.

Market Beat

Regeneron Pharma

Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $768.00 Price Target at Morgan Stanley

Look beyond the healthcare company's recent setbacks.

2 reasons to buy Regeneron stock like there's no tomorrow

VRTX

Vertex Pharmaceuticals Inc. (VRTX) shares rose 1.37% to $452.04, outperforming competitors during a rough trading session where the S&P 500 and Dow Jones fell. This marks the third consecutive day of gains for Vertex, which remains 13.02% below its 52-week high. Trading volume was higher than the 50-day average.

Dow Jones

Vertex Pharma

Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

AMGN

Amgen announced that the FDA has approved Uplizna for the treatment of adults with generalized myasthenia gravis who test positive for specific antibodies. The treatment involves twice-yearly dosing after initial doses and is supported by phase 3 study results. Uplizna showed significant improvement in symptoms compared to placebo, with benefits lasting up to 52 weeks. Common side effects included headache and infusion-related reactions.

fidelity

Amgen

Amgen Says FDA Approves Uplizna For Autoimmune Disorder Treatment

Regeneron Pharmaceuticals Inc. (REGN) shares rose 2.84% to $746.80 on Thursday, outperforming competitors like Amgen, Moderna, and Gilead Sciences. This marked the stock's second consecutive day of gains. The S&P 500 Index rose 0.21% and the Dow Jones Industrial Average rose 1.34%. Trading volume matched its 50-day average. REGN is 5.59% short of its 52-week high of $790.98 reached on November 26th.

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

VP Andrew J. Murphy of Regeneron Pharmaceuticals Inc. surrendered 4,229 shares valued at $2,966,686 to cover option exercise costs and tax liabilities. His ending holdings are 52,208 shares. The transaction was disclosed in a Form 4 filed with the SEC on December 11, 2025.

Reuters

VP Murphy Surrenders 4,229 Of Regeneron Pharmaceuticals Inc [REGN]

Regeneron Pharmaceuticals Inc Vice President McCourt Marion surrendered 1,021 shares on December 9, 2025, valued at $716,242, to cover option exercise costs and/or tax liabilities. Ending holdings are 14,546 shares.

VP McCourt Surrenders 1,021 Of Regeneron Pharmaceuticals Inc [REGN]

RARE

Howard Horn, CFO of Ultragenyx Pharmaceutical Inc., reported selling common shares of the company. The filing is available via EDGAR, the SEC's system. This AI-generated news is for informational purposes and not financial advice.

Ultragenyx Pharma

Ultragenyx CFO Howard Horn Reports Sale of Common Shares

Chris Boulton, former head of global marketing for obesity at Amgen, has been appointed CEO of Prolynx, a biotech focused on developing longer-acting drug candidates for obesity. Prolynx, still in the preclinical phase, aims to improve obesity treatment with once-monthly and once-quarterly medicines. The company has raised $70 million in series A funding to advance its pipeline towards clinical proof-of-concept.

Fiercepharma

Amgen obesity marketing head Boulton departs to lead Prolynx

The FDA has approved Amgen's UPLIZNA® for treating generalized myasthenia gravis (gMG) in adults with anti-AChR and anti-MuSK antibodies. UPLIZNA, a CD19-targeted B cell therapy, offers durable symptom control with twice-yearly dosing. The approval is based on the Myasthenia Gravis Inebilizumab Trial (MINT), which showed significant efficacy and steroid tapering benefits. This marks the third indication for UPLIZNA, previously approved for NMOSD and IgG4-RD. Common adverse reactions include headache and infusion-related reactions.

StockTitan

FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS | AMGN Stock News

BMO Capital's Evan Seigerman maintained a Buy rating on Regeneron with a price target of $850. Seigerman, a 5-star analyst, focuses on healthcare stocks. Truist Financial also issued a Buy rating, while Scotiabank maintained a Hold rating on Regeneron.

Tip Ranks

Regeneron (REGN) Receives a Buy from BMO Capital

INSM

Nebula Research & Development LLC increased its stake in Insmed, Inc. by 985% in Q2, now holding 36,661 shares worth $3.69 million. Other investors also adjusted their positions. Insmed's stock performance showed a 52.4% revenue increase YoY, despite a Q3 EPS loss of $1.75. Analysts have given positive ratings, with price targets ranging from $135 to $215.

Insmed

Insmed, Inc. $INSM Shares Acquired by Nebula Research & Development LLC

ALNY

Alnylam Pharmaceuticals Inc. has repurchased $34.4 million of its 2027 Convertible Senior Notes for $51.9 million, including interest. The repurchase price is linked to Alnylam's stock price over a measurement period starting December 11, 2025. $362.8 million of the notes remain outstanding, and capped call transactions related to these notes are still in effect.

Alnylam Pharma

Alnylam Repurchases $34.4 Million of 2027 Convertible Notes for $51.9 Million

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Amgen with a price target of $325. Bansal, a 5-star analyst with an average return of 11.4%, covers the Healthcare sector. The general consensus rating for Amgen is Moderate Buy with an average price target of $339.13.

Wells Fargo Remains a Hold on Amgen (AMGN)

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Regeneron with a price target of $745. RBC Capital also issued a Hold rating, while HSBC maintained a Buy rating. Bansal, a 5-star analyst, covers the Healthcare sector with an average return of 11.4% and a 59.06% success rate.

Wells Fargo Keeps Their Hold Rating on Regeneron (REGN)